A method for evaluating pathogen inactivation effect
By using the maximum effective pathogen inactivation value (MVEPI) as the evaluation standard, the problem of non-standardization and incomparability of the evaluation of pathogen inactivation effect in the prior art is solved, and the direct evaluation of the pathogen inactivation effect and maximum inactivation ability are achieved. Comparative, has wide application value.
Patent Information
- Application Number
- CN202210779876.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-04
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2042-07-04
AI Technical Summary
The existing method for evaluating the effect of pathogens is an indirect evaluation method. Different results are obtained by different initial concentrations of pathogens used, and they cannot reflect the maximum inactivation ability of the inactivation method, and lack standardization and comparability.
The maximum effective pathogen inactivation value (MVEPI) is used as the parameter to compare the inactivation effect. After different concentrations of pathogen solutions are processed according to the same inactivation method, the maximum value of the log reduction factor is calculated and linear fitting analysis is obtained. The maximum effective pathogen inactivation value is used to evaluate the inactivation effect.
It provides a method to directly evaluate the inactivation effect of pathogens, which is suitable for evaluating the maximum inactivation ability of different technologies and methods, has wide application and good stability, and has accurate and effective evaluation results.
Smart Images

Figure CN115125286B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for evaluating the effect of pathogen inactivation. Background Art
[0002] Pathogen inactivation technology is crucial to ensure the biological safety of biological products, food, environment, etc. The effect evaluation and development of pathogen inactivation technology are inseparable from reliable pathogen inactivation effect detection methods.
[0003] Pathogen inactivation technology is crucial to ensure the biological safety of biological products, food, environment, etc. The evaluation and development of pathogen inactivation technology are inseparable from reliable pathogen inactivation effect detection methods. In 1964, Lowbury et al. proposed the percentage of pathogen count reduction to evaluate the effectiveness of different skin disinfection methods in the operating room, that is, the percentage of pathogen inactivation reduction in the total number of pathogens. With the increase of the titer of the detected pathogen, it becomes more and more difficult to accurately count the concentration of pathogens. In 1977, Jean Davies et al. proposed to overcome this problem by log conversion of the counts. Subsequently, in 1978, they proposed the concept of log reduction factor (log RF) in the evaluation of the effectiveness of skin disinfection methods. The total log value of the virus count before disinfection was subtracted from the total log value of the count after disinfection, and then the arithmetic mean (average log RF) of the log reduction factor of each sample was calculated. The difference between the average log reduction factor of each reagent was detected by statistical analysis, and the pathogen count reduction percentage was combined to comprehensively evaluate the pathogen inactivation effect of different technologies. At present, most of the pathogen inactivation effects from different industries are expressed in log reduction factors, and a small number of articles still use log reduction factors and / or pathogen count reduction percentages to express them.
[0004] The two methods currently used, log reduction factor and pathogen count reduction percentage, are both indirect evaluation methods, difficult to standardize, lack comparability in the evaluation of different inactivation methods, and cannot evaluate the maximum inactivation capacity of different inactivation methods. For example, using different initial concentrations of pathogens may result in different log reduction factors, using low concentrations of pathogens limits the reportable pathogen inactivation effect, and using high concentrations of pathogens may cause pathogens to aggregate and affect the pathogen inactivation effect (Forbes, HAS, Viral Clearance Strategies for Biopharmaceutical Safety. Pharmaceutical Technology, 2001. 25: p. 26-31).
[0005] Therefore, there is an urgent need to provide a method for directly evaluating the inactivation effect of pathogens, which can be used to evaluate the maximum inactivation capacity of different technologies and methods, or to compare the inactivation capacity of different inactivation technologies and methods. Summary of the invention
[0006] In view of the defects that the existing pathogen inactivation effect evaluation method is an indirect evaluation method, which uses different initial pathogen concentrations to obtain different results and cannot reflect the maximum inactivation capacity of the inactivation method, and thus lacks standardization and comparability, the present invention provides a new pathogen inactivation effect evaluation method: a method for comparing inactivation effects using the Maximum Value of Effective Pathogen Inactivation (MVEPI) as a parameter.
[0007] The present invention provides a method for evaluating the inactivation effect of pathogens, comprising the steps of evaluating the inactivation effect using the maximum effective pathogen inactivation value as a standard reference indicator;
[0008] The maximum effective pathogen inactivation value is: the maximum value of the log reduction factor after pathogen solutions of different concentrations before inactivation are treated according to the same inactivation method.
[0009] Furthermore, the above log reduction factor is:
[0010] log RF=lg(N / N0)=lgN-lgN0;
[0011] Where log RF is the log reduction factor, N is the pathogen concentration before inactivation, and N0 is the pathogen concentration after inactivation.
[0012] Furthermore, the above pathogen concentrations before inactivation and after inactivation are detected by in vitro culture counting, or are detected and calculated by PCR method or chemical method.
[0013] Furthermore, the above pathogen is a bacterium, a virus, a parasite, a protozoa or a rickettsia.
[0014] Furthermore, the above-mentioned bacteria is Escherichia coli or Staphylococcus aureus, and the virus is vesicular stomatitis virus.
[0015] Furthermore, the above pathogen is a pathogen marked with a marker, and the marker is: a radioactive marker, a fluorescent marker or a chemical marker.
[0016] Furthermore, the above maximum effective pathogen inactivation value is obtained by linear fitting analysis with the concentration of the pathogen solution before inactivation as the independent variable and its corresponding log reduction factor as the dependent variable;
[0017] Alternatively, the concentration of the pathogen solution before inactivation is used as the independent variable and the corresponding concentration of the pathogen solution after inactivation is used as the dependent variable for linear fitting analysis.
[0018] Furthermore, the above maximum effective pathogen inactivation value is obtained by a method comprising the following steps:
[0019] (1) preparing pathogen solutions before inactivation of different concentrations;
[0020] (2) inactivating the pathogens in the pathogen solutions prepared in step (1) according to the same inactivation method, and detecting the concentration of the pathogens in the solutions after inactivation;
[0021] (3) Calculate the log reduction factor for each solution:
[0022] log RF = lgN - lgN0;
[0023] Wherein, log RF is the log reduction factor, N is the pathogen concentration of the solution before inactivation, and N0 is the corresponding pathogen concentration of the solution after inactivation;
[0024] (4) Analyze the relationship between lgN and its corresponding log RF, take the part with a linear function relationship, use lgN as the independent variable and log RF as the dependent variable to perform linear fitting, and obtain the linear fitting function:
[0025] D=f(C)
[0026] Where D is log RF, C is lgN;
[0027] (5) Let D = C in the straight line fitting function and calculate the value of C, which is the maximum effective pathogen inactivation value.
[0028] Furthermore, the above maximum effective pathogen inactivation value is obtained by a method comprising the following steps:
[0029] (1') preparing pathogen solutions before inactivation of different concentrations;
[0030] (2') inactivating the pathogens in the pathogen solutions prepared in step (1') according to the same inactivation method, and detecting the concentration of the pathogens in the solutions after inactivation;
[0031] (3') calculating the logarithmic values of pathogen concentrations in pathogen solutions before inactivation of different concentrations and their corresponding pathogen solutions after inactivation, lgN and lgN0, where N is the pathogen concentration of the solution before inactivation and N0 is the corresponding pathogen concentration of the solution after inactivation;
[0032] (4') Analyze the relationship between lgN and lgN0, take the part with linear function relationship, take lgN as the independent variable and lgN0 as the dependent variable to perform linear fitting, and obtain the linear fitting function:
[0033] D'=f(C')
[0034] Among them, D' is lgN0, C' is lgN0;
[0035] (5') Let D' = 0 in the linear fitting function and calculate the value of C', which is the maximum effective pathogen inactivation value.
[0036] Furthermore, the above method also includes the following error control step:
[0037] (a') preparing m portions of the same pathogen solution before inactivation as in step (1) according to the method of step (1) as the control solution;
[0038] (b') culturing the pathogens in the control solution obtained in step (a') and the inactivated solution obtained in step (2) under the same conditions for the same time, comparing the growth rates of the pathogens in the control solution obtained in step (a') and the corresponding inactivated solution obtained in step (2), and repeating the test if the growth rate error reaches more than 1 standard deviation.
[0039] Beneficial effects of the present invention: The method provided by the present invention for evaluating the pathogen inactivation effect using the Maximum Value of Effective Pathogen Inactivation (MVEPI) as a parameter is a method for directly evaluating the pathogen inactivation effect, which is suitable for evaluating the maximum inactivation capacity of different technologies and methods, or for comparing the inactivation capacity of different inactivation technologies and methods. It has a wide range of applications and good stability, and the evaluation results are accurate and effective, and has promotion and application value.
[0040] The term "pathogen concentration" of the present invention refers to the concentration of surviving pathogens, which includes pathogen titer, concentration or values related to pathogen concentration detected by various methods; pathogen count, TCID50, pathogen nucleic acid detection CT value, etc., which can be converted to obtain the value of pathogen concentration, all belong to the definition of "pathogen concentration" of the present invention. The acquisition method includes but is not limited to: culturing the pathogen after diluting it in multiples, calculating the pathogen titer according to the growth of the pathogen, and then converting it to obtain the concentration of surviving pathogens; adding a colorimetric reagent (bacterial live or dead dye) to the pathogen, and obtaining the concentration of surviving pathogens by detecting the colorimetric reagent; directly detecting the specific survival characteristics of the pathogen to obtain the concentration of surviving pathogens; using flow cytometry or detecting the fluorescence intensity of the dye, the percentage of the number of stained bacteria is calculated to obtain the concentration of surviving pathogens. The pathogen concentration is obtained by changing the resonant frequency of the terahertz (THz) metamaterial element sensor coated with a pathogen-free layer with temperature.
[0041] The concentration gradient design of the "pathogen solutions before inactivation of different concentrations" of the present invention can be routinely adjusted according to the common sense of those skilled in the art so as to obtain a function having a straight linear relationship.
[0042] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0043] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 : Trends in log reduction factor and initial concentration of E. coli in saline after RUV treatment.
[0045] Figure 2 : The changing trends of residual titer and initial concentration of VSV in plasma after treatment with intermediate-acting RUV.
[0046] Figure 3 :The changing trend of residual pathogen titer with the initial pathogen concentration (A), the results of evaluating the inactivation effect of VSV in plasma by weak RUV using MLRF method (B) and MPR method (C).
[0047] Figure 4 : Results of evaluating the inactivation effects of high-, medium-, and weak-potency RUVs using the MLRF method (A) and the MPR method (B). DETAILED DESCRIPTION
[0048] The raw materials and equipment used in the present invention are all known products, which are obtained by purchasing commercially available products.
[0049] Example 1: MVEPI value of riboflavin inactivation method for Escherichia coli and effect evaluation
[0050] 1. Experimental sample preparation
[0051] Freshly cultured E. coli (K12S lederberg) overnight was centrifuged and suspended in physiological saline, and then diluted with physiological saline to different initial concentrations (1-11 log) for later use.
[0052] 2. Sample processing
[0053] Inactivation was performed according to the method disclosed in Yin Y, Li L, Gong L, et al. Effects of riboflavin and ultravioletlight treatment on pathogen reduction and platelets [J]. Transfusion, 2020, 60 (11): 2647-2654. The saline samples containing different concentrations of E. Coli were divided into two equal parts. One part was added with 500 μmol / L riboflavin saline solution at a ratio of 1:10 as the sample group to be treated, and the final concentration of riboflavin in the sample was 50 μmol / L. The same proportion of saline was added to the other part as the control group. The samples of the control group were placed in a 4°C refrigerator during the treatment of the experimental group samples.
[0054] Take 200 μL / well of the treated group samples containing different concentrations of E. coli in physiological saline and add them to a sterile 24-well plate. TM Nunc TM ), and 6 replicate samples were taken for each concentration sample. All 24-well plates with covers containing samples were irradiated under ultraviolet light with a peak of 311 nm for 15 min.
[0055] 3. Sample testing after processing
[0056] After all the samples in the experimental groups were treated, the saline control samples containing different concentrations of pathogens in different experiments (repeated 6 times) and all the samples after treatment were diluted 10X and cultured on the corresponding culture medium (E. Coli was cultured in BHI (Brain Heart infusion broth). After 2-4 days, the growth of pathogens was observed and recorded. The pathogen titer was calculated using the Reed-Muench method. Finally, the pathogen inactivation log reduction factor and the pathogen count reduction percentage were calculated using the pathogen growth before and after inactivation.
[0057] 4. Experimental Statistics
[0058] We conducted a correlation analysis on the amount of residual pathogens after inactivation of pathogens in each experimental condition, as well as the calculated log reduction factor after inactivation and the growth of pathogens before inactivation. When P < 0.05, there was a correlation. The data groups with correlation were subjected to regression analysis, and the regression equation containing the constant term was tested for significance using variance analysis. When P < 0.05, the difference was considered to be significant and the regression equation was meaningful.
[0059] 5. Experimental results
[0060] 5.1 Analysis of results of traditional pathogen inactivation effect evaluation methods
[0061] The bacterial growth, log reduction factor, and pathogen count reduction percentage of physiological saline containing different concentrations of E. coli after RUV treatment for 15 minutes are shown in Table 1. Figure 1 .
[0062] Table 1 Inactivation effect of riboflavin photochemical method on different concentrations of E. coli in saline (n=3)
[0063]
[0064] Note: When the pathogen residual concentration is lower than the detection limit, we will uniformly record the pathogen residual concentration as 0 in the calculation of the inactivation effect in this table.
[0065] 5.2 MVEPI value proposed
[0066] It can be seen that when the initial concentration of E.coli is less than or equal to 7.67±0.17log, the log reduction factor of bacterial inactivation increases with the increase of initial concentration, and no bacterial residues can be detected. When the initial bacterial concentration exceeds 7.67±0.17log, the amount of bacterial residue increases with the increase of the initial concentration of the pathogen, and is linearly positively correlated with the initial concentration, Y=5.115X-40.475 (P=0.026, Y is the residual concentration of E.col, X is the initial concentration of E.col), and the log reduction factor decreases with the increase of the initial bacterial concentration, and is negatively linearly correlated with the initial concentration, Y=40.475-4.113X (P=0.033, Y is the log reduction factor, X is the initial concentration of E.col). Assuming that when the residual amount is close to 0, that is, the equation Y = 5.115X-40.475 = 0 (P = 0.026, Y is the residual concentration of E.col, X is the initial concentration of E.col), or the log reduction factor is equal to the initial concentration, Y = 40.475-4.113X = X, the calculated X value represents the maximum effective E.col inactivation value (MVEPI) when the residual is close to 0 under this inactivation condition, which is 7.91.
[0067] Example 2: Evaluation of the inactivation effect of riboflavin on vesicular stomatitis virus (VSV)
[0068] 1. Experimental sample preparation
[0069] Vesicular stomatitis virus (VSV; VR-1238 TM ) was first diluted to different concentrations (1-7log) with saline, and then added to plasma at a ratio of 1:10 to obtain plasma containing different concentrations of virus. The plasma was obtained from Deyang Central Blood Station and approved by the local ethics committee.
[0070] 2. Sample processing
[0071] It is divided into three methods: high-efficiency RUV inactivation VSV treatment, medium-efficiency RUV inactivation VSV treatment, and weak-efficiency RUV inactivation VSV treatment. The basic treatment method is the same as that in Example 1, except that the light wavelength and dosage used are different:
[0072] High efficiency: 311nm irradiation dose 12.98J / mL; medium efficiency: 311nm irradiation dose 6.49J / mL; low efficiency: 365nm irradiation dose 12.56J / mL. According to Yin Y, Li L, Gong L, et al. Effects of riboflavin and ultraviolet light treatment on pathogen reduction and platelets[J]. Transfusion, 2020, 60(11): 2647-2654. Public reports, the inactivation effects of the above-mentioned inactivation methods are as follows from high to low: high efficiency > medium efficiency > low efficiency.
[0073] 3. Sample testing after processing
[0074] Same as Example 1.
[0075] 4. Experimental Statistics
[0076] Same as Example 1.
[0077] 5. Experimental results
[0078] When using the intermediate-acting RUV to inactivate VSV in plasma, when the VSV concentration is ≤3.75±0.22, the log reduction factor increases with the increase of the initial concentration; when the VSV concentration is ≥4.26±0.28, the residual amount of VSV increases with the increase of the initial concentration, Y(residual concentration)=1.483X(initial concentration)-5.985(P=0.001), while the log reduction factor decreases with the increase of the initial concentration and is linearly negatively correlated with the initial concentration, Y(log reduction factor)=5.985-0.483X(initial concentration)(P=0.007). The trend of the residual titer and initial concentration of VSV in plasma after RUV treatment is as follows Figure 2 The calculated MVEPI value is 4.04.
[0079] The use of weak RUV to inactivate VSV in plasma also demonstrated the applicability of MVEPI. When the VSV concentration was lower than 1.56±0.13, the log reduction factor after inactivation increased with the increase of initial concentration. When the VSV concentration was ≥2.48±0.25log, the residual amount of VSV after inactivation increased with the increase of initial concentration, Y(residual amount)=1.264X(initial concentration)-2.241(P<0.001); the log reduction factor after inactivation decreased with the increase of initial concentration, Y(log reduction factor)=2.241-0.264X(initial concentration)(P<0.001); the MVEPI calculated using the residual degree and log reduction factor was 1.77.
[0080] When the highly efficient RUV inactivated VSV in plasma, the maximum detection limit was exceeded, that is, the MVEPI exceeded 5.99, and the accurate value could not be obtained.
[0081] From the comparison of the above results, according to the size of MVEPI: high efficiency (MVEPI value greater than 5.99), medium efficiency MVEPI value is 4.04, and low efficiency MVEPI value is 1.77. It can be judged that the inactivation effect is high efficiency > medium efficiency > low efficiency, which is consistent with the actual situation reported in the literature. It proves that the method of the present invention using the size of the MVEPI value to evaluate the inactivation effect is accurate and effective, and has good sensitivity and stability.
[0082] Comparative Example 1, Evaluation Results of MLRF and MPR Methods
[0083] Escherichia coli was inactivated according to the method of Example 1, and then the two most commonly used inactivation effect evaluation methods were used: (1) the mean log reduction factor method (MLRF method, i.e., the inactivation effect was expressed by log RF); and (2) the mean percentage reduction method (MPR, i.e., the inactivation effect was expressed by the percentage reduction of pathogen counts) to verify the accuracy and stability of the above evaluation methods at different initial concentrations.
[0084] The results are as follows Figure 3 shown. Figure 3 A is the change in the measured residual pathogen titer as the initial pathogen titer increases. Figure 3 B and 3C are the evaluation results of MLRF and MPR methods respectively. It can be seen that a pathogen inactivation effect close to 100% can be achieved by using a lower initial concentration of pathogens, while the logRF of the MLRF method is lower due to detection limitations. The count reduction percentage of the MRP method using a high concentration of pathogens may be less than 100%, and the logRF and count reduction percentage vary with different initial concentrations.
[0085] For example, when the initial concentration of E. coli was 7.67±0.17, the logRF after inactivation was 7.67±0.17, and the percentage of pathogen count reduction was close to 100%, while when the initial concentration of E. coli was 9.50±0.11, the percentage of pathogen count reduction was 96.84±0.37%, and the logRF was only 1.50±0.16. Therefore, for different initial E. coli titers, different MLRF and MPR results were obtained after treatment with riboflavin and ultraviolet light under the same conditions. Therefore, it is impossible to accurately evaluate the maximum inactivation capacity of this method by the percentage of pathogen count reduction and logRF.
[0086] Similarly, VSV was inactivated by referring to the method of Example 2, and the MLRF method and MPR method were used for evaluation. The results are as follows: Figure 4 As shown in Figure 2, the sensitivity of MPR was poor, as there was little difference between the high and medium EPI groups ( Figure 4 B); log RF can sensitively show differences in EPI, but the results vary greatly depending on the initial titer ( Figure 4 A).
[0087] In summary, the present invention provides a method for evaluating the pathogen inactivation effect using the Maximum Value of Effective Pathogen Inactivation (MVEPI) as a parameter. The present invention is a method for directly evaluating the pathogen inactivation effect, which is suitable for evaluating the maximum inactivation capacity of different technologies and methods, or for comparing the inactivation capacity of different inactivation technologies and methods. It has a wide range of applications, good stability, accurate and effective evaluation results, and has promotion and application value.
Claims
1. A method for evaluating the effect of pathogen inactivation, characterized in that: It includes the steps of evaluating the inactivation effect by taking the maximum effective pathogen inactivation value as the standard reference index; The maximum effective pathogen inactivation value is: the maximum value of the log reduction factor after the pathogen solutions before inactivation of different concentrations are treated according to the same inactivation method; The log reduction factor is: log RF=lg(N / N0)=lgN-lgN0; Wherein, log RF is the log reduction factor, N is the pathogen concentration before inactivation, and N0 is the pathogen concentration after inactivation; The maximum effective pathogen inactivation value is obtained by linear fitting analysis using the concentration of the pathogen solution before inactivation as the independent variable and the corresponding log reduction factor as the dependent variable; the maximum effective pathogen inactivation value is obtained by a method comprising the following steps: (1) preparing pathogen solutions before inactivation of different concentrations; (2) inactivating the pathogens in the pathogen solutions prepared in step (1) according to the same inactivation method, and detecting the concentration of the pathogens in the solutions after inactivation; (3) Calculate the log reduction factor for each solution: log RF = lgN - lgN0; Wherein, log RF is the log reduction factor, N is the pathogen concentration of the solution before inactivation, and N0 is the corresponding pathogen concentration of the solution after inactivation; (4) Analyze the relationship between lgN and its corresponding log RF, take the part with a linear function relationship, use lgN as the independent variable and log RF as the dependent variable to perform linear fitting, and obtain the linear fitting function: D=f(C) Where D is log RF, C is lgN; (5) Let D = C in the straight line fitting function and calculate the value of C, which is the maximum effective pathogen inactivation value.
2. The evaluation method according to claim 1, characterized in that: The pathogen concentration before inactivation and the pathogen concentration after inactivation are detected by in vitro culture counting, or are detected and calculated by a PCR method or a chemical method, or are obtained by thermal curve analysis using a terahertz (THz) metamaterial.
3. The evaluation method according to claim 1, wherein: The pathogen is a bacterium, virus, parasite, protozoa or rickettsia.
4. The evaluation method according to claim 3, characterized in that: The bacteria is Escherichia coli or Staphylococcus aureus, and the virus is vesicular stomatitis virus.
5. The evaluation method according to claim 1, wherein: The pathogen is a pathogen marked with a marker, and the marker is a chemical marker.
6. The evaluation method according to claim 1, wherein: The pathogen is a pathogen labeled with a marker, and the marker is a radioactive marker or a fluorescent marker.
7. The evaluation method according to claim 1, characterized in that: It also includes the following error control steps: (a') preparing m portions of the same pathogen solution before inactivation as in step (1) according to the method of step (1) as the control solution; (b') culturing the pathogens in the control solution obtained in step (a') and the inactivated solution obtained in step (2) under the same conditions for the same time, comparing the growth rates of the pathogens in the control solution obtained in step (a') and the corresponding inactivated solution obtained in step (2), and repeating the test if the growth rate error reaches more than 1 standard deviation.
